The F.D.A. is considering the rare move of revoking their approval of the breast cancer drug Avastin because the benefits of the drug may not outweigh the risks. Medical experts made a recommendation to the F.D.A. earlier this year condemning the drug due to its potential toxic side effects and extremely high cost. Recent studies show Avastin does not prolong a users’ life for any considerable amount of time. Experts say Avastin has drastic side effects, including “blood clots, bleeding, and heart failure.”